Corpus ID: 17957562

Apolipoprotein B ( ApoB ) and apolipoprotein A 1 The Apolipoprotein B / A 1 Ratio is Associated with Reactive Oxygen Metabolites and Endothelial Dysfunction in Statin-Treated Patients with Coronary Artery Disease

@inproceedings{Emoto2013ApolipoproteinB,
  title={Apolipoprotein B ( ApoB ) and apolipoprotein A 1 The Apolipoprotein B / A 1 Ratio is Associated with Reactive Oxygen Metabolites and Endothelial Dysfunction in Statin-Treated Patients with Coronary Artery Disease},
  author={Takuo Emoto and Takahiro Sawada and Natsumi Morimoto and T. Tenjin and T. Wakimoto and F. Ikeda and C. Sato and Daisuke Terashita and T. Mizoguchi and Takao Mizuguchi and H. Okamoto and Yosuke Matsuo and Sushi-ku Kim and A. Takarada and M. Yokoyama},
  year={2013}
}
  • Takuo Emoto, Takahiro Sawada, +12 authors M. Yokoyama
  • Published 2013
    • There is convincing evidence that statin treatment significantly reduces the risk of cardiac events in patients with dyslipidemia . The administration of statins is strongly recommended for the primary and secondary prevention of coronary artery disease (CAD). Specifically, the American Heart Association and American College of Cardiology Foundation (AHA/ ACCF) guidelines set the goal of statin treatment for the secondary prevention of CAD in patients with low density lipoprotein (LDL… CONTINUE READING
    jstage.jst.go.jp

    Tables from this paper

    Tables

    References

    SHOWING 1-10 OF 24 REFERENCES
    ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients
    • 21
    A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    • M. Davidson
    • Medicine
    • The American journal of cardiology
    • 2008
    • 27
    Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    • 3,380
    • PDF
    Established and emerging plasma biomarkers in the prediction of first atherothrombotic events.
    • 430
    • PDF
    AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.
    • 1,438
    • PDF
    Increased reactive oxygen metabolites is associated with cardiovascular risk factors and vascular endothelial damage in middle-aged Japanese subjects
    • 32
    • PDF
    Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
    • 1,940
    • PDF
    Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
    • 29
    Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study
    • 80
    • PDF
    Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes
    • 409
    • PDF